A bispecific T-cell engager antibody (BiTE) against TAG-72/CD3 for targeted cancer immunotherapy

被引：0
|
作者：
Khambati, Fatema [1 ]
Soliman, Hatem [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2395
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2395
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
    Kebenko, Maxim
    Goebeler, Marie-Elisabeth
    Wolf, Martin
    Hasenburg, Annette
    Seggewiss-Bernhardt, Ruth
    Ritter, Barbara
    Rautenberg, Beate
    Atanackovic, Djordje
    Kratzer, Andrea
    Rottman, James B.
    Friedrich, Matthias
    Vieser, Eva
    Elm, Stefanie
    Patzak, Ingrid
    Wessiepe, Dorothea
    Stienen, Sabine
    Fiedler, Walter
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [32] T-cell engaging bispecific outer membrane vesicles (BiTE-OMV) for targeted prostate cancer immunotherapy
    Kang, Jeonbin
    Kim, Kyumin
    Ju, Seoyeong
    Jin, Seongwoo
    Kim, Jimin
    Kim, Seunghwan
    Kim, Byung Seok
    Jose, Joachim
    Pyun, Jae-Chul
    Lee, Misu
    Bong, Ji-Hong
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2025, 107
  • [33] CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy
    Humbert, Olivier
    Llewellyn, Mallory J.
    Laszlo, George S.
    Walter, Roland B.
    Kiem, Hans-Peter
    BLOOD, 2019, 134
  • [34] NURSING EXPERIENCE MONITORING AND MANAGEMENT OF PATIENTS RECEIVING TARLATAMAB, A BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, FOR SMALL CELL LUNG CANCER (SCLC)
    Gray, Sunshine
    Pons, Alba Silverio
    Kelley, Elaine
    McDonald, Stephanie
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [35] Bispecific T-cell engager (BiTE) immunotherapy of ovarian cancer based on MIL-88A MOF/MC gene delivery system
    Zhao, Jing
    Lu, Danping
    Moya, Sergio
    Yan, Haoying
    Qiu, Miaojuan
    Chen, JunZong
    Wang, Xincheng
    Li, Yang
    Pan, Haobo
    Chen, Guochuang
    Wang, Guocheng
    APPLIED MATERIALS TODAY, 2020, 20
  • [36] Cellular mechanism of action of bispecific T-cell engager (BiTE®) antibody constructs targeting Folate Receptor 1
    Bailis, Julie M.
    Orf, Jessica N.
    Sternjak, Alexander
    Belmontes, Brian
    Case, Ryan
    Grinberg, Natalia
    Chang, Wesley
    Hinkle, Beth
    Friedrich, Matthias
    CANCER RESEARCH, 2016, 76
  • [37] Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa)
    Paweletz, Katherine L.
    Li, Shyun
    Bailis, Julie M.
    Juan, Gloria
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [38] Therapeutic bispecific T-cell engager antibody targeting the transferrin receptor
    Fu, M.
    Guo, Z.
    Tang, H.
    Zhu, H.
    Shen, G.
    Lei, P.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1768 - 1768
  • [39] Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
    Fu, Mingpeng
    He, Qi
    Guo, Zilong
    Zhou, Xiaoran
    Li, Heli
    Zhao, Liang
    Tang, Hongling
    Zhou, Xiaoqi
    Zhu, Huifen
    Shen, Guanxin
    He, Yong
    Lei, Ping
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [40] Development of GD2 and CD3 Targeted Bispecific T-Cell Engaging Antibodies for Neuroblastoma
    Patel, A.
    Thevanesan, C.
    Anderson, J.
    Pule, M.
    Straathof, K.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S136 - S137
12345